Stock Events

Stock Events

QurientLtd 

₩15,840
2
-₩970-5.77% 06:30 Today

Statistics

Day High
16,700
Day Low
15,400
52W High
62,900
52W Low
14,330
Volume
113,440
Avg. Volume
189,505
Mkt Cap
589.03B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Financials

-430.41%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
6.98BRevenue
-30.05BNet Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap211.7B
Gilead Sciences is a biopharmaceutical company that develops similar therapeutic drugs in areas like antiviral drugs, competing directly with Qurient's focus on novel therapeutics.
Vertex Pharmaceuticals
VRTX
Mkt Cap141.65B
Vertex Pharmaceuticals focuses on creating new drugs to treat serious diseases, similar to Qurient's approach in drug development for unmet medical needs.
Regeneron Pharmaceuticals
REGN
Mkt Cap95.99B
Regeneron Pharmaceuticals is known for its innovation in biopharmaceuticals, directly competing with Qurient in the field of novel drug discovery and development.
AMGEN
AMGN
Mkt Cap251.94B
Amgen develops innovative human therapeutics, a direct competitor in the biotechnology industry focusing on novel treatments similar to Qurient.
Biogen
BIIB
Mkt Cap37.49B
Biogen's focus on developing novel therapies for neurological and neurodegenerative diseases places it in direct competition with Qurient's therapeutic development.
Incyte
INCY
Mkt Cap24.54B
Incyte Corporation specializes in oncology products, competing with Qurient which is also involved in developing treatments for cancer.
Biomarin Pharmaceutical
BMRN
Mkt Cap11.33B
BioMarin Pharmaceutical targets rare genetic diseases with its drug development efforts, competing in the same niche as Qurient.
Exelixis
EXEL
Mkt Cap16.93B
Exelixis is involved in the discovery, development, and commercialization of new medicines for challenging cancers, directly competing with Qurient's cancer-focused therapies.

About

Qurient Co., Ltd., a biotech company, engages in the research and development of drugs to address unmet medical needs in Korea and internationally. The company's pipeline products include Q301, a topical 5LO inhibitor, which is in Phase II clinical trial for the treatment of atopic dermatitis; and Telacebec (Q203), Cyt bc1 Inhibitor, that is in Phase II to treat Mycobacterial Infections, such as tuberculosis/non-TBM. Its pipeline products also comprise Adrixetinib (Q702), an Axl/Mer/CSF1R Inhibitor, which completed phase I for the treatment of solid tumors; and Q901, a selective CDK7 inhibitor, is under Phase I stage for treating solid tumors. The company was formerly known as Quro Science Inc. and changed its name to Qurient Co., Ltd. in October 2011. Qurient Co., Ltd. was founded in 2008 and is headquartered in Seongnam-si, South Korea.
Show More
CEO
Dr. Ki-Yean Nam
Employees
31
Country
South Korea
ISIN
KR7115180002

Listings

KQ
KR
115180.KQ

0 Comments

Share your thoughts

FAQs

What is QurientLtd stock price today?▼
The current price of 115180.KQ is ₩15,840 KRW — it has decreased by -5.77% in the past 24 hours. Watch QurientLtd stock price performance more closely on the chart.
What is QurientLtd stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on KOSDAQ exchange QurientLtd stocks are traded under the ticker 115180.KQ.
Is QurientLtd stock price growing?▼
115180.KQ stock has fallen by -14.1% compared to the previous week, the month change is a -36% fall, over the last year QurientLtd has showed a -20.2% decrease.
What is QurientLtd market cap?▼
Today QurientLtd has the market capitalization of 589.03B
What is QurientLtd revenue for the last year?▼
QurientLtd revenue for the last year amounts to 6.98B KRW.
What is QurientLtd net income for the last year?▼
115180.KQ net income for the last year is -30.05B KRW.
How many employees does QurientLtd have?▼
As of November 3, 2026, the company has 31 employees.
In which sector is QurientLtd located?▼
QurientLtd operates in the Energy sector.
When did QurientLtd complete a stock split?▼
The last stock split for QurientLtd was on December 18, 2023 with a ratio of 1.3:1.
Where is QurientLtd headquartered?▼
QurientLtd is headquartered in Seongnam-si, South Korea.